Completed PHASE4 INTERVENTIONAL 2-arm NCT01785758

Efficacy and Safety of Sugammadex in Renal Diseased Patients

Efficacy and Safety of Sugammadex (Bridion™) in the Reversal of Profound Rocuronium-induced Neuromuscular Blockade in Patients With End-stage Renal Failure: Comparison With Healthy Patients

Sponsor: Federal University of São Paulo

Conditions Kidney Failure, Chronic Neuromuscular Blockade

Interventions Sugammadex (4 mg/Kg)

Updated 5 times since 2017 Last updated: Feb 5, 2013 Started: Oct 31, 2011 Primary completion: Jan 31, 2012 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01785758, this PHASE4 trial focuses on Kidney Failure, Chronic and Neuromuscular Blockade and remains completed. Sponsored by Federal University of São Paulo, it has been updated 5 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Federal University of São Paulo
Hospital General Universitario Santa Lucía

Data source: Federal University of São Paulo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• São Paulo, Brazil